Short Interest in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Increases By 46.2%

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) was the recipient of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 658,100 shares, a growth of 46.2% from the December 31st total of 450,000 shares. Approximately 2.6% of the shares of the stock are sold short. Based on an average daily volume of 276,000 shares, the short-interest ratio is presently 2.4 days.

Institutional Trading of Vistagen Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. HighTower Advisors LLC purchased a new stake in shares of Vistagen Therapeutics in the 3rd quarter valued at approximately $64,000. Jane Street Group LLC acquired a new stake in Vistagen Therapeutics during the 3rd quarter valued at $59,000. American Century Companies Inc. lifted its holdings in shares of Vistagen Therapeutics by 49.1% in the second quarter. American Century Companies Inc. now owns 30,315 shares of the company’s stock valued at $105,000 after purchasing an additional 9,984 shares in the last quarter. Valence8 US LP acquired a new stake in shares of Vistagen Therapeutics in the third quarter worth $103,000. Finally, Virtu Financial LLC grew its holdings in shares of Vistagen Therapeutics by 30.5% during the third quarter. Virtu Financial LLC now owns 20,210 shares of the company’s stock valued at $61,000 after buying an additional 4,722 shares in the last quarter. Institutional investors and hedge funds own 78.39% of the company’s stock.

Vistagen Therapeutics Price Performance

Shares of Vistagen Therapeutics stock traded down $0.05 during trading on Friday, hitting $2.89. The stock had a trading volume of 218,479 shares, compared to its average volume of 199,775. The business has a fifty day moving average of $2.78 and a two-hundred day moving average of $3.06. The firm has a market cap of $80.46 million, a P/E ratio of -2.33 and a beta of 0.78. Vistagen Therapeutics has a fifty-two week low of $2.22 and a fifty-two week high of $5.74.

Vistagen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.02). The business had revenue of $0.18 million during the quarter, compared to analyst estimates of $0.34 million. Vistagen Therapeutics had a negative return on equity of 36.35% and a negative net margin of 4,521.71%. During the same period in the prior year, the firm earned ($0.66) EPS. As a group, research analysts forecast that Vistagen Therapeutics will post -1.85 earnings per share for the current year.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.